Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China · Delayed Price · Currency is CNY 12.97
+0.39 (3.10%)
Oct 29, 2026, 3:00 PM CST
SHE:002727 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 7,446 | 7,383 | 7,625 | 13,803 | 18,782 | 22,959 | |
Market Cap Growth | -6.89% | -3.16% | -44.76% | -26.51% | -18.19% | 15.78% |
Enterprise Value | 6,333 | 7,156 | 7,679 | 13,717 | 19,101 | 23,481 |
Last Close Price | 12.58 | 12.40 | 12.17 | 21.25 | 28.48 | 34.26 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 19.59 | 28.03 | 66.80 | 25.12 | 18.60 | 24.91 |
Forward PE | 16.31 | 12.43 | 10.17 | 13.00 | 16.59 | 19.48 |
PS Ratio | 0.42 | 0.43 | 0.42 | 0.79 | 1.08 | 1.57 |
PB Ratio | 0.95 | 0.99 | 1.00 | 1.75 | 2.50 | 3.44 |
P/TBV Ratio | 1.39 | 1.46 | 1.44 | 2.33 | 3.20 | 4.52 |
P/FCF Ratio | 3.93 | 5.45 | 5.20 | 7.41 | 8.74 | 16.40 |
P/OCF Ratio | 3.38 | 4.52 | 4.43 | 6.53 | 7.52 | 12.81 |
PEG Ratio | - | 3.48 | 3.48 | 0.73 | 0.98 | 0.93 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 0.36 | 0.41 | 0.43 | 0.79 | 1.10 | 1.61 |
EV/EBITDA Ratio | 2.21 | 11.24 | 15.26 | 14.16 | 13.34 | 18.30 |
EV/EBIT Ratio | 9.80 | 13.54 | 20.04 | 16.25 | 14.50 | 19.81 |
EV/FCF Ratio | 3.32 | 5.28 | 5.24 | 7.37 | 8.89 | 16.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.30 | 0.36 | 0.40 | 0.38 | 0.41 | 0.44 |
Debt / EBITDA Ratio | 0.82 | 1.50 | 1.85 | 1.50 | 1.33 | 1.28 |
Debt / FCF Ratio | 1.24 | 1.96 | 2.07 | 1.61 | 1.44 | 2.08 |
Net Debt / Equity Ratio | -0.17 | -0.05 | -0.05 | -0.11 | -0.06 | 0.06 |
Net Debt / EBITDA Ratio | -1.76 | -0.64 | -0.75 | -0.93 | -0.30 | 0.29 |
Net Debt / FCF Ratio | -0.69 | -0.30 | -0.26 | -0.48 | -0.20 | 0.27 |
Asset Turnover | 1.09 | 1.07 | 1.08 | 1.06 | 1.14 | 1.23 |
Inventory Turnover | 3.30 | 3.05 | 3.13 | 3.26 | 3.43 | 3.38 |
Quick Ratio | 0.76 | 0.72 | 0.70 | 0.80 | 0.82 | 0.70 |
Current Ratio | 1.34 | 1.30 | 1.27 | 1.37 | 1.38 | 1.31 |
Return on Equity (ROE) | 4.98% | 3.60% | 1.42% | 7.28% | 14.27% | 14.73% |
Return on Assets (ROA) | 2.49% | 2.04% | 1.43% | 3.21% | 5.40% | 6.26% |
Return on Invested Capital (ROIC) | 6.56% | 4.93% | 2.86% | 9.56% | 15.28% | 20.17% |
Return on Capital Employed (ROCE) | 7.30% | 6.00% | 4.20% | 8.90% | 14.20% | 14.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.10% | 3.57% | 1.50% | 3.98% | 5.38% | 4.01% |
FCF Yield | 25.44% | 18.35% | 19.22% | 13.49% | 11.44% | 6.10% |
Dividend Yield | 3.08% | 3.11% | 2.30% | 1.73% | 1.27% | 0.78% |
Payout Ratio | 65.27% | 115.74% | 228.27% | 47.40% | 18.97% | 19.63% |
Buyback Yield / Dilution | 2.86% | 2.70% | 0.76% | -0.27% | -0.50% | -3.32% |
Total Shareholder Return | 5.93% | 5.81% | 3.06% | 1.46% | 0.77% | -2.54% |